CINPHA Cinclus Pharma Holding AB (publ)

1.120USD11.38 SEK · STO+0.35%Mkt Cap: 52.13M USDP/E: —

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassi…

Key Statistics

Company
Market Cap52.13M USD
Enterprise Value30.05M USD
Revenue (TTM)2.69M USD
Gross Profit3.46M USD
Net Income (TTM)-18.11M USD
Revenue/Share0.06 USD
Last Price1.120 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees14
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0020388577
Valuation
P/E (Trailing)—
P/E (Forward)-2.01
PEG—
EV/EBITDA-0.86
EV/Revenue11.18
P/S19.40
P/B8.07
EPS (TTM)-0.72 USD
EPS (Forward)—
52W Range
1.0439% of range1.933
52W High1.933 USD
52W Low1.043 USD
Profitability
Gross Margin100.00%
Oper. Margin-1303.16%
EBITDA Margin0.00%
Profit Margin-320.12%
ROE-49.80%
ROA-33.66%
ROIC—
ROCE-48.36%
Growth
Revenue Growth-80.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.35M USD
CapEx (TTM)111.62K USD
FCF Margin-515.60%
FCF Yield-26.58%
Net Debt-22.08M USD
Net Debt/EBITDA0.63
Net Debt/FCF—
Balance Sheet
Debt/Equity0.02
Current Ratio1.44
Quick Ratio1.33
Book Value/Sh0.14 USD
Cash/Share0.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.429 USD
Upside (mean)+295.4%
Target Range2.461 USD – 6.890 USD
2.461+295.4% to mean6.890
# Analysts4
Ownership
Shares Out.46.54M
Float34.29M
Insiders29.95%
Institutions36.42%
Technical
SMA 501.199 (-6.6%)
SMA 2001.313 (-14.7%)
Beta0.06
S&P 52W Chg12.00%
Avg Vol (30d)34.14K
Avg Vol (10d)71.26K
Technical Indicators
RSI (14)41.1
MACD-0.2394
MACD Signal-0.2217
MACD Hist.-0.0176
BB Upper1.211 USD
BB Middle1.152 USD
BB Lower1.092 USD
BB Width10.32%
ATR (14)0.0525 USD
Vol Ratio (20d)0.29x

About Cinclus Pharma Holding (STO: CINPHA)

›

Cinclus Pharma Holding (STO: CINPHA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 14 employees.

The shares were at 11.38 SEK on 19 November 2026, down 36.7% over 52 weeks. Its 52-week range is 10.60 SEK to 19.64 SEK: the price is 42.1% below the high and 7.4% above the low.

Its market capitalisation is 529.60M SEK.

Cinclus Pharma Holding reports return on equity of -49.8% and revenue down 80.8% year over year.

It holds more cash than debt, a net cash position of 224.28M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 45.00 SEK is 295.4% above the current price.